ArticleHealth economics review2025

Matters arising: cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing-remitting multiple sclerosis: a systematic review.

Carlo Lazzaro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.